LEGN20270319P7.5
LEGN Mar 19 2027 7.50 Put (LEGN270319P00007500)
option OPRA

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o